These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results
1. MRVI reported losses of 8 cents per share, missing estimates. 2. Quarterly sales reached $46.85 million, exceeding expectations of $44.01 million. 3. Projected FY2025 sales range is $185M to $205M, slightly below estimates. 4. Analysts adjusted price targets; one maintained Buy but lowered it. 5. Shares fell 3.5% post-announcement, indicating market reaction.